Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01618305 · ClinicalTrials.gov registry record · Phase 4
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
A Phase 4 study, sponsored by Westat.
- Completed
- Registry status
- Phase 4
- Development phase
- 408
- Enrollment target
NCT01618305 is a Phase 4 study that has completed, run by Westat. The registered enrollment target is 408 participants.
The verdict
NCT01618305, a Phase 4 study, has completed, sponsored by Westat.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 408 participants
- Enrollment target
Study Summary
HIV-infected pregnant women who begin taking antiretroviral (ARV) medications in the late stages of pregnancy need an effective medication regimen to reduce the risk of transmitting HIV to their children. This study examined the virologic response, safety, and tolerability of two different ARV medication regimens in HIV-infected pregnant women who were between 20 and 36 weeks pregnant when they entered the study.
Interventions
- DRUG Efavirenz
- DRUG Raltegravir
- DRUG Lamivudine/zidovudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2013-09-05 |
| Est. Completion | 2018-12-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01618305
The ClinicalTrials.gov registry entry for NCT01618305 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Westat, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Efavirenz is the first listed.
NCT01618305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01618305 about?
NCT01618305 is a clinical study titled "Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission". HIV-infected pregnant women who begin taking antiretroviral (ARV) medications in the late stages of pregnancy need an effective medication regimen to reduce the risk of transmitting HIV to their children. This study examined the virologic response, safety, and tolerability of two different ARV medic...
What is the current status of trial NCT01618305?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 408 participants. The study started on 2013-09-05. Estimated completion is 2018-12-11.
What interventions are being tested in trial NCT01618305?
The interventions under investigation include: Efavirenz (DRUG), Raltegravir (DRUG), Lamivudine/zidovudine (DRUG).
Who is sponsoring clinical trial NCT01618305?
This trial is sponsored by Westat, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.